Find information on thousands of medical conditions and prescription drugs.

Dubin-Johnson syndrome

Dandy-Walker syndrome
Darier's disease
Demyelinating disease
Dengue fever
Dental fluorosis
Dentinogenesis imperfecta
Depersonalization disorder
Dermatitis herpetiformis
Dermatographic urticaria
Desmoplastic small round...
Diabetes insipidus
Diabetes mellitus
Diabetes, insulin dependent
Diabetic angiopathy
Diabetic nephropathy
Diabetic neuropathy
Diamond Blackfan disease
Diastrophic dysplasia
Dibasic aminoaciduria 2
DiGeorge syndrome
Dilated cardiomyopathy
Dissociative amnesia
Dissociative fugue
Dissociative identity...
Dk phocomelia syndrome
Double outlet right...
Downs Syndrome
Duane syndrome
Dubin-Johnson syndrome
Dubowitz syndrome
Duchenne muscular dystrophy
Dupuytren's contracture
Dyskeratosis congenita
Dysplastic nevus syndrome


[List your site here Free!]

Hyperbilirubinemia in the Term Newborn
From American Family Physician, 2/15/02 by Meredith L. Porter

Hyperbilirubinemia is one of the most common problems encountered in term newborns. Historically, management guidelines were derived from studies on bilirubin toxicity in infants with hemolytic disease. More recent recommendations support the use of less intensive therapy in healthy term newborns with jaundice. Phototherapy should be instituted when the total serum bilirubin level is at or above 15 mg per dL (257 [micro]mol per L) in infants 25 to 48 hours old, 18 mg per dL (308 [micro]mol per L) in infants 49 to 72 hours old, and 20 mg per dL (342 [micro]mol per L) in infants older than 72 hours. Few term newborns with hyperbilirubinemia have serious underlying pathology. Jaundice is considered pathologic if it presents within the first 24 hours after birth, the total serum bilirubin level rises by more than 5 mg per dL (86 [micro]mol per L) per day or is higher than 17 mg per dL (290 [micro]mol per L), or an infant has signs and symptoms suggestive of serious illness. The management goals are to exclude pathologic causes of hyperbilirubinemia and initiate treatment to prevent bilirubin neurotoxicity. (Am Fam Physician 2002;65:599-606,613-4. Copyright[C] 2002 American Academy of Family Physicians.)

Neonatal hyperbilirubinemia, defined as a total serum bilirubin level above 5 mg per dL (86 [micro]mol per L), is a frequently encountered problem. Although up to 60 percent of term newborns have clinical jaundice in the first week of life, few have significant underlying disease.(1,2) However, hyperbilirubinemia in the newborn period can be associated with severe illnesses such as hemolytic disease, metabolic and endocrine disorders, anatomic abnormalities of the liver, and infections.

Jaundice typically results from the deposition of unconjugated bilirubin pigment in the skin and mucus membranes. Depending on the underlying etiology, this condition may present throughout the neonatal period. Unconjugated hyperbilirubinemia, the primary focus of this article, is the most common form of jaundice encountered by family physicians. The separate topic of conjugated hyperbilirubinemia is beyond the scope of this article.

Risk Factors for Hyperbilirubinemia

Infants without identified risk factors rarely have total serum bilirubin levels above 12 mg per dL (205 [micro]mol per L). As the number of risk factors increases, the potential to develop markedly elevated bilirubin levels also increases.(2)

Common risk factors for hyperbilirubinemia include fetal-maternal blood group incompatibility, prematurity, and a previously affected sibling (Table 1).(2-4) Cephalohematomas, bruising, and trauma from instrumented delivery may increase the risk for serum bilirubin elevation. Delayed meconium passage also increases the risk. Infants with risk factors should be monitored closely during the first days to weeks of life.

Bilirubin Production and Newborns

Bilirubin is the final product of heme degradation. At physiologic pH, bilirubin is insoluble in plasma and requires protein binding with albumin. After conjugation in the liver, it is excreted in bile.(3,5-7)

Newborns produce bilirubin at a rate of approximately 6 to 8 mg per kg per day. This is more than twice the production rate in adults, primarily because of relative polycythemia and increased red blood cell turnover in neonates.(7) Bilirubin production typically declines to the adult level within 10 to 14 days after birth.(2)

Bilirubin Toxicity

"Kernicterus" refers to the neurologic consequences of the deposition of unconjugated bilirubin in brain tissue. Subsequent damage and scarring of the basal ganglia and brain-stem nuclei may occur.(5)

The precise role of bilirubin in the development of kernicterus is not completely understood. If the serum unconjugated bilirubin level exceeds the binding capacity of albumin, unbound lipid-soluble bilirubin crosses the blood-brain barrier. Albumin-bound bilirubin may also cross the blood-brain barrier if damage has occurred because of asphyxia, acidosis, hypoxia, hypoperfusion, hyperosmolality, or sepsis in the newborn.(3,8)

The exact bilirubin concentration associated with kernicterus in the healthy term infant is unpredictable.(1) Toxicity levels may vary among ethnic groups, with maturation of an infant, and in the presence of hemolytic disease. Although the risk of bilirubin toxicity is probably negligible in a healthy term newborn without hemolysis,(9) the physician should become concerned if the bilirubin level is above 25 mg per dL (428 [micro]mol per L).(1,3,10) In the term newborn with hemolysis, a bilirubin level above 20 mg per dL (342 [micro]mol per L) is a concern.(1,3)

The effects of bilirubin toxicity are often devastating and irreversible (Table 2).(3,9) Early signs of kernicterus are subtle and nonspecific, typically appearing three to four days after birth. However, hyperbilirubinemia may lead to kernicterus at any time during the neonatal period.(2) After the first week of life, the affected newborn begins to demonstrate late effects of bilirubin toxicity. If the infant survives the initial severe neurologic insult, chronic bilirubin encephalopathy (evident by three years of age) leads to developmental and motor delays, sensorineural deafness, and mild mental retardation.

Classification of Neonatal Hyperbilirubinemia

The causes of neonatal hyperbilirubinemia can be classified into three groups based on mechanism of accumulation: bilirubin overproduction, decreased bilirubin conjugation, and impaired bilirubin excretion (Table 3).(11)


Physiologic jaundice in healthy term newborns follows a typical pattern. The average total serum bilirubin level usually peaks at 5 to 6 mg per dL (86 to 103 [micro]mol per L) on the third to fourth day of life and then declines over the first week after birth.(2) Bilirubin elevations of up to 12 mg per dL, with less than 2 mg per dL (34 [micro]mol per L) of the conjugated form, can sometimes occur. Infants with multiple risk factors may develop an exaggerated form of physiologic jaundice in which the total serum bilirubin level may rise as high as 17 mg per dL (291 [micro]mol per L).(3)

Factors that contribute to the development of physiologic hyperbilirubinemia in the neonate include an increased bilirubin load because of relative polycythemia, a shortened erythrocyte life span (80 days compared with the adult 120 days), immature hepatic uptake and conjugation processes, and increased enterohepatic circulation.(7)


Early-Onset Breastfeeding Jaundice. Breastfed newborns may be at increased risk for early-onset exaggerated physiologic jaundice because of relative caloric deprivation in the first few days of life.(12) Decreased volume and frequency of feedings may result in mild dehydration and the delayed passage of meconium. Compared with formula-fed newborns, breastfed infants are three to six times more likely to experience moderate jaundice (total serum bilirubin level above 12 mg per dL) or severe jaundice (total serum bilirubin level above 15 mg per dL [257 [micro]mol per L]).(12,13)

In a breastfed newborn with early-onset hyperbilirubinemia, the frequency of feedings needs to be increased to more than 10 per day. If the infant has a decline in weight gain, delayed stooling, and continued poor caloric intake, formula supplementation may be necessary, but breastfeeding should be continued to maintain breast milk production. Supplemental water or dextrose-water administration should be avoided, as it decreases breast milk production and places the newborn at risk for iatrogenic hyponatremia.(3,5,11)

Late-Onset Breast Milk Jaundice. Breast milk jaundice occurs later in the newborn period, with the bilirubin level usually peaking in the sixth to 14th days of life. This late-onset jaundice may develop in up to one third of healthy breastfed infants.(1) Total serum bilirubin levels vary from 12 to 20 mg per dL (340 [micro]mol per L) and are nonpathologic.

The underlying cause of breast milk jaundice is not entirely understood. Substances in maternal milk, such as b-glucuronidases, and nonesterified fatty acids, may inhibit normal bilirubin metabolism.(5,7,14,15) The bilirubin level usually falls continually after the infant is two weeks old, but it may remain persistently elevated for one to three months.

If the diagnosis of breast milk jaundice is in doubt or the total serum bilirubin level becomes markedly elevated, breastfeeding may be temporarily interrupted, although the mother should continue to express breast milk to maintain production. With formula substitution, the total serum bilirubin level should decline rapidly over 48 hours (at a rate of 3 mg per dL [51 [micro]mol per L] per day),1 confirming the diagnosis. Breastfeeding may then be resumed.


All etiologies of jaundice beyond physiologic and breastfeeding or breast milk jaundice are considered pathologic. Features of pathologic jaundice include the appearance of jaundice within 24 hours after birth, a rapidly rising total serum bilirubin concentration (increase of more than 5 mg per dL per day), and a total serum bilirubin level higher than 17 mg per dL in a full-term newborn.(3,5) Other features of concern include prolonged jaundice, evidence of underlying illness, and elevation of the serum conjugated bilirubin level to greater than 2 mg per dL or more than 20 percent of the total serum bilirubin concentration. Pathologic causes include disorders such as sepsis, rubella, toxoplasmosis, occult hemorrhage, and erythroblastosis fetalis.



The presence of jaundice can be determined by examining the infant in a well-lit room and blanching the skin with digital pressure to reveal the color of the skin and subcutaneous tissue. Neonatal dermal icterus is not noticeable at total serum bilirubin levels below 4 mg per dL (68 [micro]mol per L).(16)

Increasing total serum bilirubin levels are accompanied by the cephalocaudal progression of dermal icterus, predictably from the face to the trunk and extremities, and finally to the palms and soles.(16,17) The total serum bilirubin level can be estimated clinically by the degree of caudal extension: face, 5 mg per dL; upper chest, 10 mg per dL (171 [micro]mol per L); abdomen, 12 mg per dL; palms and soles, greater than 15 mg per dL.

The only consistently reliable estimation of total serum bilirubin occurs when dermal icterus is confined to above the nipple line. In this situation, the bilirubin level is invariably below 12 mg per dL. As jaundice extends below the middle of the chest, the correlation between physical signs and measured bilirubin levels becomes increasingly unreliable. Differences in skin color among races, delays in dermal deposition with rapidly rising bilirubin levels, interobserver variability, and other factors contribute to the difficulty of accurately predicting the total serum bilirubin concentration based on caudal progression alone.(18)

The physical examination should focus on identifying one of the known causes of pathologic jaundice. The infant should be assessed for pallor, petechiae, extravasated blood, excessive bruising, hepatosplenomegaly, weight loss, and evidence of dehydration.


The initial evaluation of jaundice depends on the age of the newborn (Figure 1).2 If the serum conjugated bilirubin level is above 2 mg per dL, the infant should be evaluated for possible hepatocellular disease or biliary obstruction.


Studies on the toxic effects of hyperbilirubinemia historically involved infants with hemolytic disease. An increased incidence of kernicterus was found to be associated with total serum bilirubin levels above 20 mg per dL in the presence of hemolysis.(19,20) This observation was the basis for aggressive guidelines recommending the use of exchange transfusion in all infants with significant hyperbilirubinemia. More recently, term infants without hemolysis have been found to tolerate higher total serum bilirubin levels,(21) and management guidelines now focus primarily on phototherapy as initial treatment.(1)

Recommendations for the management of hyperbilirubinemia in healthy term newborns have been outlined by the American Academy of Pediatrics (Table 4).(1) Jaundice in a term newborn fewer than 24 hours old is always pathologic: it should be investigated thoroughly and treated appropriately. Depending on the rate at which the bilirubin level rises, a newborn's risk of developing significant hyperbilirubinemia can be classified as low, intermediate, or high (Figure 2).(22) With the assumption that the bilirubin level will continue to rise at the same rate, the physician can predict the potential further progression of the rise and calculate the number of days that the infant may be at risk for bilirubin toxicity.

Conjugated hyperbilirubinemia is never physiologic, and it may indicate the presence of a potentially serious underlying disorder. However, elevated conjugated bilirubin levels are not directly toxic to brain cells in the neonate.(2)

If jaundice persists for more than two weeks in a formula-fed infant and more than three weeks in a breastfed infant, further evaluation is warranted.(1,7) Laboratory studies should include a fractionated bilirubin level, thyroid studies, evaluations for metabolic disorders or hemolytic disease, and an assessment for intestinal obstruction.


Before treatment is initiated, the minimum evaluation should include the infant's age and postnatal course, a maternal and gestational history, physical examination of the infant, and determination of the total serum bilirubin level and the rate at which it is rising (Figure 2).(22)


Phototherapy employs blue wavelengths of light to alter unconjugated bilirubin in the skin. The bilirubin is converted to less toxic water-soluble photoisomers that are excreted in the bile and urine without conjugation. The decision to initiate phototherapy is based on the newborn's age and total serum bilirubin level (Table 4).(1)

The efficacy of phototherapy depends on several important factors. The ideal configuration is four special blue bulbs (F20T12/BB) placed centrally, with two daylight fluorescent tubes on either side. The power output of the lights (irradiance) is directly related to the distance between the lights and the newborn.(23) Ideally, all lights should be 15 to 20 cm from the infant.(2) To expose the greatest surface area, the newborn should be naked except for eye shields. For double phototherapy, a fiber-optic pad can be placed under the newborn. This method is twice as effective as standard phototherapy.(5)

The only contraindication to the use of phototherapy is conjugated hyperbilirubinemia, as occurs in patients with cholestasis and hepatic disease. In this setting, phototherapy may cause a dark grayish-brown discoloration of the skin (bronze baby syndrome).(2) Potential problems that may occur with phototherapy include burns, retinal damage, thermoregulatory instability, loose stools, dehydration, skin rash, and tanning of the skin. Because phototherapy is continuous, treatment also involves significant separation of the infant and parents.

With intensive phototherapy, the total serum bilirubin level should decline by 1 to 2 mg per dL (17 to 34 [micro]mol per L) within four to six hours.(1,5) The bilirubin level may decline more slowly in breastfed infants (rate of 2 to 3 mg per dL per day) than in formula-fed infants.(3) Phototherapy usually can be discontinued when the total serum bilirubin level is below 15 mg per dL.(1) The average rebound bilirubin level after phototherapy is below 1 mg per dL. Therefore, hospital discharge of most infants does not have to be delayed to monitor for rebound elevation.(24,25)

If the total serum bilirubin level remains elevated after intensive phototherapy or if the initial bilirubin level is meets defined critical levels based on the infant's age (Table 4),(1) preparations should be made for exchange transfusion.


Exchange transfusion is the most rapid method for lowering serum bilirubin concentrations. This treatment is rarely needed when intensive phototherapy is effective.(1,26,27) The procedure removes partially hemolyzed and antibody-coated erythrocytes and replaces them with uncoated donor red blood cells that lack the sensitizing antigen.

In the presence of hemolytic disease, severe anemia, or a rapid rise in the total serum bilirubin level (greater than 1 mg per dL per hour in less than six hours), exchange transfusion is the recommended treatment. Exchange transfusion should be considered in a newborn with nonhemolytic jaundice if intensive phototherapy fails to lower the bilirubin level.(1)

Complications of exchange transfusion can include air embolism, vasospasm, infarction, infection, and even death. Because of the potential seriousness of these complications, intensive phototherapy efforts should be exhausted before exchange transfusion is initiated.26

The authors indicate that they do not have any conflicts of interest. Sources of funding: none reported.

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Army Medical Department or the U.S. Army at large.

MEREDITH L. PORTER, CPT, MC, USA, is a staff family physician at Vicencza Army Health Clinic, Italy. Dr. Porter received her medical degree from Virginia Commonwealth University School of Medicine, Richmond, and completed a family practice residency at Dewitt Army Community Hospital, Fort Belvoir, Va.

BETH L. DENNIS, MAJ, MC, USA, is a staff family physician and clinic director at Dewitt Army Community Hospital. She also serves as assistant professor of medicine at the Uniformed Services University of Health Sciences F. Edward Hebert School of Medicine, Bethesda, Md. Dr. Dennis received her medical degree from the University of Virginia School of Medicine, Charlottesville, and completed a family practice residency at Tripler Army Medical Center, Honolulu.

Address correspondence to Meredith L. Porter, CMR 427, Box 3389, APO, AE 09630 (e-mail: Reprints are not available from the authors.


(1.) Practice parameter: management of hyperbilirubinemia in the healthy term newborn. Pediatrics 1994;94(4 pt 1):558-62.

(2.) Jaundice and hyperbilirubinemia in the newborn. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson Textbook of pediatrics. 16th ed. Philadelphia: Saunders, 2000:511-28.

(3.) Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med 2001;344:581-90.

(4.) Clemons RM. Issues in newborn care. Prim Care 2000;27:251-67.

(5.) Melton K, Akinbi HT. Neonatal jaundice. Strategies to reduce bilirubin-induced complications. Postgrad Med 1999;106:167-8,171-4,177-8.

(6.) Wintrobe MM, Lee GR. Wintrobe's Clinical hematology. 10th ed. Baltimore: Williams & Wilkins, 1999:267-89.

(7.) Gartner LM, Herschel M. Jaundice and breastfeeding. Pediatr Clin North Am 2001;48:389-99.

(8.) Ravel R. Clinical laboratory medicine: clinical application of laboratory data. 6th ed. St. Louis: Mosby, 1999:309-27.

(9.) Maisels MJ, Newman TB. Kernicterus in otherwise healthy, breast-fed term newborns. Pediatrics 1995;96(4 pt 1):730-3.

(10.) Newman TB, Maisels MJ. Evaluation and treatment of jaundice in the term newborn: a kinder, gentler approach. Pediatrics 1992;89(5 pt 1):809-18.

(11.) Siberry GK, Iannone R, eds. The Harriet Lane handbook: a manual for pediatric house officers. 15th ed. St. Louis: Mosby, 2000:257-8.

(12.) Osborn LM, Reiff MI, Bolus R. Jaundice in the full-term neonate. Pediatrics 1984;73:520-5.

(13.) Schneider AP II. Breast milk jaundice in the newborn. A real entity. JAMA 1986;255:3270-4.

(14.) Poland RL. Breast-milk jaundice. J Pediatr 1981;99: 86-8.

(15.) Brodersen R, Herman LS. Intestinal reabsorption of unconjugated bilirubin. Lancet 1963;1:1242.

(16.) Kramer LI. Advancement of dermal icterus in the jaundiced newborn. Am J Dis Child 1969;118:454-8.

(17.) Knudsen A, Ebbesen F. Cephalocaudal progression of jaundice in newborns admitted to neonatal intensive care units. Biol Neonate 1997;71:357-61.

(18.) Moyer VA, Ahn C, Sneed S. Accuracy of clinical judgment in neonatal jaundice. Arch Pediatr Adolesc Med 2000;154:391-4.

(19.) Hsai DY, Allen FH, Gellis SS, Diamond LK. Erythroblastosis fetalis. VIII. Studies of serum bilirubin in relation to kernicterus. N Engl J Med 1952;247:668-71.

(20.) Gartner LM, Herrarias CT, Sebring RH. Practice patterns in neonatal hyperbilirubinemia. Pediatrics 1998;101(1 pt 1):25-31.

(21.) Newman TB, Maisels MJ. Does hyperbilirubinemia damage the brain of healthy full-term infants? Clin Perinatol 1990;17:331-58.

(22.) Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999;103:6-14.

(23.) Maisels MJ. Why use homeopathic doses of phototherapy? Pediatrics 1996;98(2 pt 1):283-7.

(24.) Yetman RJ, Parks DK, Huseby V, Mistry K, Garcia J. Rebound bilirubin levels in infants receiving phototherapy. J Pediatr 1998;133:705-7.

(25.) Lazar L, Litwin A, Merlob P. Phototherapy for neonatal nonhemolytic hyperbilirubinemia. Clin Pediatr [Phila] 1993;32:264-7.

(26.) Jackson JC. Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics 1997;99:E7.

(27.) Brown AK, Kim MH, Wu YK, Bryla DA. Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia. Pediatrics 1985;75(2 pt 2):393-400.

COPYRIGHT 2002 American Academy of Family Physicians
COPYRIGHT 2002 Gale Group

Return to Dubin-Johnson syndrome
Home Contact Resources Exchange Links ebay